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Abstract
Background: Obesity and insulin resistance are two major risk factors underlying the metabolic syndrome. The
development of these metabolic disorders is frequently studied, but mainly in liver, skeletal muscle, and adipose
tissue. To gain more insight in the role of the small intestine in development of obesity and insulin resistance,
dietary fat-induced differential gene expression was determined along the longitudinal axis of small intestines of
C57BL/6J mice.
Methods: Male C57BL/6J mice were fed a low-fat or a high-fat diet that mimicked the fatty acid composition of
a Western-style human diet. After 2, 4 and 8 weeks of diet intervention small intestines were isolated and divided
in three equal parts. Differential gene expression was determined in mucosal scrapings using Mouse genome 430
2.0 arrays.
Results: The high-fat diet significantly increased body weight and decreased oral glucose tolerance, indicating
insulin resistance. Microarray analysis showed that dietary fat had the most pronounced effect on differential gene
expression in the middle part of the small intestine. By overrepresentation analysis we found that the most
modulated biological processes on a high-fat diet were related to lipid metabolism, cell cycle and inflammation.
Our results further indicated that the nuclear receptors Ppars, Lxrs and Fxr play an important regulatory role in
the response of the small intestine to the high-fat diet. Next to these more local dietary fat effects, a secretome
analysis revealed differential gene expression of secreted proteins, such as Il18, Fgf15, Mif, Igfbp3 and Angptl4.
Finally, we linked the fat-induced molecular changes in the small intestine to development of obesity and insulin
resistance.
Conclusion: During dietary fat-induced development of obesity and insulin resistance, we found substantial
changes in gene expression in the small intestine, indicating modulations of biological processes, especially related
to lipid metabolism. Moreover, we found differential expression of potential signaling molecules that can provoke
systemic effects in peripheral organs by influencing their metabolic homeostasis. Many of these fat-modulated
genes could be linked to obesity and/or insulin resistance. Together, our data provided various leads for a causal
role of the small intestine in the etiology of obesity and/or insulin resistance.
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Background
Metabolic syndrome is a multi-component condition
associated with a high risk of type 2 diabetes mellitus and
cardiovascular disease [1]. In industrialized societies,
approximately 20–40% of the population is affected by
the metabolic syndrome and its incidence is expected to
rise even further in the next decades [2]. Obesity and insu-
lin resistance are two major risk factors underlying the
metabolic syndrome. Obesity is considered the principal
causal factor of insulin resistance, which is the pivotal
metabolic disturbance in the metabolic syndrome [3].
Lifestyle factors, such as nutrition and limited physical
activity, are known to contribute to the pathogenesis of
obesity and insulin resistance. The association between
development of these disorders and excessive intake of
dietary fat is frequently studied, especially in obesity-
prone C57BL/6J mice [4-8]. Most of these studies focused
on the physiology and underlying molecular mechanisms
in liver, skeletal muscle and adipose tissue, as these organs
are target organs of insulin-modulated metabolism [9-
11]. However, there is growing evidence that also the
small intestine can play a role in the etiology of obesity
and/or insulin resistance, as it serves as a gatekeeper at the
physical interphase between body and diet. Efficient
absorption and metabolic processing of nutrients is a
major function of the small intestine, in which various
nuclear receptors are likely to play an important regula-
tory role. Additionally, the enterocytes in the small intes-
tine are responsible for sensing of luminal contents that
are modulated by the diet. As a result of this sensing, the
small intestine secretes signaling molecules, such as gut
hormones and pro- and anti-inflammatory cytokines, to
which liver, muscle and adipose tissue respond by modu-
lating their metabolism to keep homeostatic control.
Small intestinal factors that are previously reported to
contribute to development of metabolic syndrome are gut
hormones affecting satiety and glucose homeostasis
[12,13], diminished fatty acid oxidative capacity of ente-
rocytes [5] and gut microbiota-mediated modulations
[6,14].
In this study, microarray analysis of small intestinal
mucosa was performed to explore the role of the small
intestine in development of dietary fat-induced obesity
and/or insulin resistance in C57BL/6J mice. We deter-
mined high-fat diet-induced molecular changes along the
longitudinal axis of the small intestine, at different time
points during a Western-style humanized high-fat diet
intervention. We analyzed the biological processes in the
small intestine that are affected by feeding a high-fat diet
and determined the involvement of nuclear receptors in
gene expression changes. Beside the molecular changes
that provoke a more local effect in the small intestine, we
further studied the differential gene expression of (novel)
small intestinal secreted proteins that are able to induce
systemic effects. Therefore, an additional secretome anal-
ysis was performed. Finally, we linked the molecular
changes found in the small intestine after high-fat diet
feeding to development of obesity and insulin resistance.
Methods
Animals and diets
Male C57BL/6J mice (age 4 weeks) were purchased from
Harlan (Horst, The Netherlands) and were housed in the
light and temperature-controlled animal facility (12/12
(light/dark), 20°C) of Wageningen University. They had
free access to water and received standard laboratory chow
(RMH-B, Arie Blok BV, Woerden, The Netherlands) for
two weeks, followed by the low-fat diet for three weeks to
adapt to the purified diets. All experiments were approved
by the Ethical Committee on animal testing of Wagenin-
gen University. To investigate the effect of dietary fat on
development of obesity and insulin resistance and on
small intestinal gene expression in C57BL/6J mice, we
used low-fat (reference) and high-fat diets that are based
on 'Research Diets' formulas D12450B/D12451, with
adaptations regarding type of fat (palm oil in stead of
lard) and carbohydrates to mimic the fatty acid and carbo-
hydrate composition of the average human diet in West-
ern societies (Research diet services, Wijk bij Duurstede,
The Netherlands). Thus, the high-fat diet mimics the ratio
of saturated to monounsaturated to polyunsaturated fatty
acids (40:40:20) in a human diet. The complete composi-
tion of the diets is given in Additional file 1. It should be
noted that in these diets the energy density of all nutrients,
except fat and starch, is equal.
At the start of the diet intervention, the mice were divided
into two groups and were fed a powdered high- or a low-
fat purified diet. After 2, 4, and 8 weeks of diet interven-
tion, 6 mice per diet group, per time point were sacrificed
after they were anaesthetized with a mixture of iso-
fluorane (1.5%), nitrous oxide (70%) and oxygen (30%).
All mice were sacrificed in the postprandial state and diur-
nal variability was avoided by harvesting small intestines
at the same time of the day for both diet groups. The small
intestines were divided into three equal parts along the
longitudinal axis (proximal, middle and distal part of the
small intestine). Small intestinal epithelial cells were
scraped, snap-frozen in liquid nitrogen, and stored at -
80°C until RNA isolation. Body weight was recorded
weekly. The mice that were sacrificed after 8 weeks of diet
intervention were all subjected to an oral glucose toler-
ance test (OGTT) at week 7. Therefore, after 6-hours fast-
ing, all mice received 0.5 ml of a 20% glucose solution via
an oral gavage and blood glucose was measured after 15,
30, 45, 60, 90 and 150 minutes using Accu-Chek blood
glucose meters (Roche Diagnostics, Almere, The Nether-
lands). To determine food intake, non-absorbable chro-BMC Medical Genomics 2008, 1:14 http://www.biomedcentral.com/1755-8794/1/14
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mic oxide was supplemented to the diets for one week
(week 5 of diet intervention). At the end of this week feces
was quantitatively collected during 48 hours and fecal
chromic oxide levels were determined as previously
described [15]. These fecal chromic oxide levels were then
used to calculate the energy intake per mouse per day on
a high-fat and low-fat diet. An outline of this study design
is presented in Additional file 2.
For immunohistochemical analysis, an identical low-fat
and high-fat diet intervention study was performed for 2
weeks (n = 12 per diet). Small intestines were again
excised, divided into three equal parts, cut open longitu-
dinally, and washed with PBS. Thereafter, the small intes-
tinal parts were fixed in 10% buffered formalin and
embedded in paraffin.
RNA isolation
Total RNA was isolated using TRIzol reagent (Invitrogen,
Breda, The Netherlands) according to the manufacturer's
instructions. The isolated RNA was further column-puri-
fied using the SV total RNA isolation system (Promega,
Leiden, The Netherlands). RNA concentration was meas-
ured on a NanoDrop ND-1000 UV-Vis spectrophotome-
ter (Isogen, Maarssen, The Netherlands) and analyzed on
a bioanalyzer (Agilent Technologies, Amsterdam, the
Netherlands) with 6000 Nano Chips according to the
manufacturer's instructions.
Microarray hybridization and analysis
Per time point, equal amounts of total RNA of six mice per
diet group were pooled for the proximal, middle and dis-
tal part of the small intestine. These pooled RNA samples
were hybridized to Mouse genome 430 2.0 arrays
(Affymetrix, Santa Clara, CA, USA). Detailed methods for
the labelling and subsequent hybridizations to the arrays
are described in the eukaryotic section in the GeneChip
Expression Analysis Technical Manual Rev. 3 from
Affymetrix, which is available upon request. Arrays were
scanned on an Affymetrix GeneChip Scanner 3000. For
microarray data analysis Microarray Analysis Suite 5.0
(MAS 5.0) was used, which is also provided by Affymetrix.
Comparison analysis by MAS 5.0 was performed to deter-
mine the dietary fat-induced differential gene expression
for each part of the small intestine per time point. To indi-
cate the magnitude and direction of differential gene
expression, MAS 5.0 software provides signal log ratio's
(SLR). If the SLR is equal to or greater than 0, fold change
is obtained with +2SLR, otherwise with -2-SLR. Array data
have been submitted to the Gene Expression Omnibus,
accession number GSE8582.
To determine overrepresentation of Gene Ontology (GO)
Biological Process subsets upon high-fat diet intervention,
an ErmineJ overrepresentation analysis (ORA) was per-
formed [16]. Gene score files that were used as input con-
tained the 'change p-values' of all probes sets provided by
MAS 5.0 comparison analysis. By setting the Gene score
threshold to a p-value of 0.0025, only significantly differ-
entially expressed genes were included in the ORA analy-
ses. Moreover, only GO subsets that contained between 2
and 125 genes were taking into account. The ErmineJ soft-
ware generally uses Benjamini-Hochberg correction of p-
values to determine which gene sets are selected with a
particular false discovery rate (FDR). The FDR is consid-
ered a rapid and reasonable guide to which gene sets are
likely to be of highest interest [16].
Heat map diagrams visualizing SLR of differentially
expressed genes were made using Spotfire DecisionSite
software by applying hierarchical clustering.
cDNA synthesis and real-time quantitative PCR
For each individual sample, single-stranded complemen-
tary DNA (cDNA) was synthesized from 1 μg of total RNA
using the Reverse transcription system (Promega, Leiden,
The Netherlands) following the supplier's protocol. cDNA
was PCR amplified with Platinum Taq DNA polymerase
(all reagents were from Invitrogen). Primer sequences (see
Additional file 3) were retrieved from the online Primer-
Bank database [17], or otherwise designed using the
Primer3 program [18]. Primers were tested for specificity
by BLAST analysis. Real-time quantitative PCR (qPCR)
was performed using SYBR green and a MyIQ thermal
cycler (Bio-Rad laboratories BV, Veenendaal, The Nether-
lands). The following thermal cycling conditions were
used: 2 min at 94°C, followed by 40 cycles of 94°C for 15
s and 60°C for 45 s. PCR reactions to validate dietary fat-
induced differential gene expression were performed in
duplicate and all samples were normalized to 18S and
cyclophilin A expression. To analyse basal gene expression
of nuclear receptors along the longitudinal axis of the
small intestine we only normalized for cyclophilin A, as
we found significant differences for 18S expression
between the proximal, middle and distal parts of the small
intestine.
Immunohistochemistry
Four-micrometer sections of paraffin-embedded distal
part of the small intestine were mounted on Superfrost
microscope slides. These sections were dewaxed in xylene
and rehydrated in a series of graded alcohols. To block
endogenous peroxidase activity, slides were incubated
with 3% H2O2 for 20 minutes. Antigen retrieval was per-
formed by placing the slides in citrate buffer (pH 6.0) and
heat them in a microwave oven 5 min 700 W (without lid)
and 4 times 5 min 500 W (with lid). After cooling down
to room temperature, the sections were briefly washed
with PBS. Prior to staining, a 20 minutes preincubation
was performed using 20% normal goat serum (VectorBMC Medical Genomics 2008, 1:14 http://www.biomedcentral.com/1755-8794/1/14
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Laboratories, Burlingame, CA, USA). The sections were
stained in a three-step procedure utilizing the following
incubations: overnight incubation at 4°C with rat mono-
clonal antibodies against Ki67 (Clone TEC-3) (DakoCyto-
mation B.V., Heverlee, Belgium), diluted 1:200 in PBS.
Thereafter, the sections were incubated with a bioti-
nylated goat-anti-rat for 30 minutes, followed by 45 min-
utes incubation with peroxidase-labelled avidin-biotin
complex (Vector Laboratories). Between all incubations,
sections were washed three times in PBS. Diaminobenzi-
dine tetrahydrochloride (DAB, Vector Laboratories) was
used as substrate to visualize the bound antibodies. After
counterstaining with Meyer's hematoxylin, sections were
mounted with DePex mounting medium (Gurr, BDH,
Poole, Dorset, UK).
Statistical analysis
Physiological data and qPCR results are reported as the
mean ± the standard error (SE) for six mice. The differ-
ences between the mean values were tested for statistical
significance by the two-tailed Student's t test.
Results
Dietary fat-induced obesity and insulin resistance in 
C57BL/6J mice
To evaluate the effect of a Western-style humanized high-
fat diet on the development of obesity and insulin resist-
ance, C57BL/6J mice were fed a high-fat versus low-fat
diet for eight weeks. Figure 1A shows that already after two
weeks on the high-fat diet, C57BL/6J mice demonstrated
a significantly higher weight gain than mice on the low-fat
diet. Moreover, an oral glucose tolerance test performed
after seven weeks of diet intervention showed that the
high-fat diet induced a significantly higher glucose intol-
erance (Figure 1B), indicating development of insulin
resistance. To determine whether these dietary effects are
confounded by higher energy intake on the high-fat diet,
we calculated food intake from the measurements of non-
absorbable chromic oxide in feces (see Methods). We
found that energy intake on the high-fat diet (10.8 ± 0.9
kcal/day) was even slightly lower, but not significantly dif-
ferent from that on the low-fat diet (11.9 ± 0.9 kcal/day).
Thus, we conclude that not the amount, but solely the
composition of the high-fat diet induced obesity and
insulin resistance in C57BL/6J mice.
Dietary fat-induced changes in small intestinal gene 
expression
After 2, 4 and 8 weeks of diet intervention, molecular
changes between the low- and high-fat diet were analyzed
for each part of the small intestine. The numbers of genes
that were differentially expressed in at least one week of
diet intervention are visualized in Figure 2. The highest
numbers of genes, transiently (grey bars) as well as contin-
uously differentially expressed during diet intervention
(black and white bars), were found in the middle part of
the small intestine. The most pronounced (-3 > fold
change > +3) and consistent molecular changes through-
out diet intervention are listed in Additional file 4. As
microarray analyses in this study were performed on
mouse samples that were pooled per diet group per time
point, qPCR was used to verify differential gene expres-
sion of randomly selected genes in individual mouse sam-
ples. In all parts of the small intestine, but especially in the
middle part, qPCR results were highly in accordance with
the microarray data (see Additional file 5). In the proxi-
mal and distal part of the small intestine, variance
between individual mouse samples was slightly higher
and therefore the qPCR results were not always signifi-
cant.
Biological processes influenced in the small intestine by 
feeding a high-fat diet
We performed an overrepresentation analysis (ORA) for
each part of the small intestine, to determine which bio-
logical processes were influenced by exposure of the small
intestine to a high-fat diet. In the ORA analysis, all genes
showing differential expression in at least one week of diet
intervention were included (Figure 3). Additionally, heat
map diagrams were created to display the number of dif-
ferentially expressed genes that were annotated to the GO
Biological Process terms listed in Figure 3 and to visualize
the magnitude and direction of their differential expres-
sion (indicated by the SLR) (Figure 4).
ORA analysis showed that biological processes related to
lipid metabolism were highly regulated by dietary fat in
all parts of the small intestine. Additionally, the heat map
diagrams in Figure 4A show that the up- or down-regula-
tion of many lipid metabolism-related genes was very
consistent in time and that dietary fat had the strongest
effect in the proximal and middle part of the small intes-
tine. In these parts, genes involved in fatty acid transport,
chylomicron synthesis and especially fatty acid oxidation
were highly up-regulated, whereas genes involved in cho-
lesterol transport were down-regulated by dietary fat. In
the distal part of the small intestine, similar regulation of
fatty acid oxidation and cholesterol transport was seen,
but less prominent than in the more proximal parts of the
small intestine. These data indicate that processing of die-
tary fat is mainly accomplished in the duodenum and
jejunum. However, the ileum is still capable of handling
the overflow of fat.
Furthermore, ORA analysis showed that dietary fat
affected the regulation of cell cycle-related processes. This
effect was most pronounced in the middle and distal parts
of the small intestine. Cell proliferation seemed to be
enhanced by dietary fat early in diet intervention, as at
these time points genes that are essential for progressionBMC Medical Genomics 2008, 1:14 http://www.biomedcentral.com/1755-8794/1/14
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Body weight and oral glucose tolerance test Figure 1
Body weight and oral glucose tolerance test. (A) Body weight gain of C57BL/6J mice during a low-fat or high-fat diet 
intervention of 8 weeks. (B) An oral glucose tolerance test was performed after 7 weeks of diet intervention. After an oral gav-
age of 100 mg glucose, blood glucose levels were monitored for 150 minutes. The changes in blood glucose levels (upper fig-
ure) and the area under he curve were calculated (lower figure). In (A) and (B), data are means ± SE. * p < 0.05. LF = low-fat 
diet, HF = high-fat diet.
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through cell cycle were up-regulated and genes involved
in apoptosis were down-regulated (Figure 4B). Remarka-
bly, after 8 weeks of diet intervention, hardly any differen-
tial gene expression related to cell cycle can be detected.
To ensure that the dietary fat-induced modulations in cell
cycle-related processes reflected proliferation of entero-
cytes and not immune cells (see below), we performed
immunohistochemistry on the distal part of the small
intestine. We found that villus length and the total
number of cells per villus were significantly higher in mice
fed the high-fat diet (Figure 5A and 5B). Additionally, we
determined proliferation rates in the villi by specific stain-
ing of proliferation marker Ki67 (Figure 5C). Differences
in Ki67-positive cells between the low-fat and high-fat
diet were most pronounced at the base of the villi, show-
ing a tendency towards an increased proliferation rate on
a high-fat diet (p = 0.07). Together these data indicate that
inhibition of apoptosis and increase in cell proliferation
induced by dietary fat results in enlargement of small
intestinal villi. This might be functional to extent the
capacity of fat absorption.
GO Biological Process subsets related to inflammation/
immune response were also overrepresented in small
intestine after feeding a high-fat diet. Figure 4C showed
that for many of these related genes the differential expres-
sion was not very consistent in time, especially in the
proximal and distal part of the small intestine. However,
in the middle part, a substantial number of genes showed
a sustained down-regulation throughout high-fat diet
intervention. Remarkably, many of these down-regulated
genes are known to be interferon gamma (IFNγ)-induci-
ble genes [19,20]. This continuous down-regulation of
genes in the middle part of the small intestine suggests a
diminished inflammatory response to the high-fat diet.
However, it remains difficult to draw a definitive conclu-
sion on inflammatory status of the overall small intestine,
as hardly any gene showed a continuous up- or down-reg-
ulation in all parts of the small intestine.
Differential gene expression of nuclear receptors and their 
target genes in the small intestine after feeding a high-fat 
diet
Nutritional modulation of metabolic pathways is fre-
quently mediated by nuclear receptors that act as ligand-
activated transcription factors [21]. In the small intestine,
we found that gene expression related to lipid metabo-
lism-related processes was highly affected after exposure
to a high-fat diet. As peroxisome proliferator activated
receptors (Ppars) and liver X receptors (Lxrs) are com-
monly linked to these pathways, we selected these nuclear
receptors to study their role in transcriptional regulation
during high-fat diet intervention. Another metabolic
nuclear receptor that might be a key regulator of the
response to dietary fat is the farnesoid X-activated receptor
(Fxr). This receptor is activated by bile acids [22], which
are supposed to be elevated in the small intestinal lumen
after feeding a high-fat diet to facilitate digestion. First, we
determined the expression of the nuclear receptors along
the longitudinal axis of the small intestine under basal
conditions (on a low-fat diet) (Figure 6). For most nuclear
receptors, the highest expression could be detected in the
middle part of the small intestine where fat absorption is
expected to be most pronounced. The highest Fxr expres-
sion was found in the ileum, the predominant site for
absorption of bile acids. Except for the continuously
down-regulation of Pparδ and co-activator Pgc1α in the
middle part of the small intestine, the effect of a high-fat
diet on nuclear receptor expression itself was minimal
(Figure 7). However, even more informative for their reg-
ulatory involvement in lipid metabolism-related proc-
esses, is the ligand-specific activation pattern of the
nuclear receptors. Therefore, we analyzed the differential
expression of the target genes of the nuclear receptors,
which reflects their activation by specific nutrients (pri-
mary diet effects; e.g. fatty acids) and/or diet-related
metabolites (secondary diet effects; e.g. biliary cholesterol
and bile acids). Pparα, -δ and -γ can all be activated by
fatty acids and in general there seems to be a substantial
overlap between the target genes of these nuclear recep-
tors. In the small intestine, the activation of Pparα is most
extensively studied and therefore we mainly focused on
Dietary fat-induced differential gene expression along the  longitudinal axis of the small intestine Figure 2
Dietary fat-induced differential gene expression 
along the longitudinal axis of the small intestine. For 
the proximal, middle and distal part of the small intestine, the 
numbers of genes that were differentially expressed in at 
least one week of diet intervention are plotted (grey bars). 
Among those are genes that were consistently up- (I) or 
down-regulated (D) on a high-fat diet (white and black bars, 
respectively).
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the differential expression of Pparα target genes as identi-
fied in Pparα null mice [23] (Figure 7). Our microarray
data clearly show that Pparα is considerably activated on
the high-fat diet, as numerous target genes were up-regu-
lated especially in the proximal and middle part of the
small intestine. As many of the target genes were also
annotated to overrepresented lipid metabolism-related
processes (Figure 3 and Figure 4A), we conclude that
Pparα plays an important regulatory role in absorption
and processing of the dietary fat in the small intestine.
Overrepresentation of GO Biological Process subsets in the small intestine during high-fat diet intervention Figure 3
Overrepresentation of GO Biological Process subsets in the small intestine during high-fat diet intervention. In 
the ORA analysis all genes showing differential expression in at least one week of diet intervention were included. For the 
proximal, middle and distal part of the small intestine, GO Biological Process subsets with a FDR < 0.01 and a RawScore = 10 
in at least one week of diet intervention are considered significantly overrepresented. Black boxes indicate 1.0E-31 < FDR < 
1.0E-08; dark grey boxes indicate 1.0E-08 < FDR < 0.01; white boxes indicate FDR > 0.01, so not significant. An empty row 
indicates that this part of small intestine did meet the above mentioned selection criteria (i.e. FDR > 0.01 at all time points).
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Heat map diagrams of differentially expressed genes on a high-fat diet Figure 4
Heat map diagrams of differentially expressed genes on a high-fat diet. SLR of differentially expressed genes related 
to lipid metabolism (A), cell cycle (B) and inflammation/immune response (C) are clustered in a heat map diagram for the prox-
imal, middle and distal part of the small intestine. Green and red indicate down- and up-regulation of gene expression, respec-
tively. In general, three expression patterns can be distinguished; consistently up-regulated, consistently down-regulated or 
alternate up- and down-regulation during diet intervention. Amongst other genes that display similar expression patterns on a 
high-fat diet, the boxes include differentially expressed genes that share association with particular biological processes (num-
bered). Differentially expressed genes with a -0.3 > SLR > 0.3 in at least one week of diet intervention were included and the 
color scheme ranges from SLR -1.5 to 1.5.
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Nuclear receptors Lxrα (Nr1h2) and Lxrβ (Nr1h3) are
known to be activated by endogenous oxysterol metabo-
lites. They control gene expression related to cholesterol
and fatty acid metabolism. Surprisingly, for these biologi-
cal processes we found quite different expression patterns
of the target genes. Cholesterol transporters ATP-binding
cassette, subfamily A1, -G5 and -G8 (Abca1,  Abcg5  and
Abcg8, respectively) were down-regulated by a high-fat
diet, whereas stearoyl-Coenzyme A desaturase 1 (Scd1) and
sterol regulatory element binding factor (Srebf1) were up-reg-
ulated. Fatty acid synthase (Fasn) showed hardly any regu-
lation. These data suggest that on a high-fat diet the
expression of these target genes is not exclusively control-
led by these Lxr receptors. Other transcription factors and
co-regulators might also be involved.
Based on the expression patterns of Fxr (Nr1h4), we
expected the most pronounced target gene regulation in
the distal part of the small intestine. However, in this part
we only found a late down-regulation of fibroblast growth
factor 15 (Fgf15), a signaling molecule that represses bile
acid synthesis in the liver. Remarkably, the most pro-
nounced differential gene expression of Fxr target genes
was found in the middle part of the small intestine,
namely a continuous up-regulation of ileal bile acid binding
protein (Ibabp) and small heterodimer partner (Shp). These
results suggest that on a high-fat diet the passive absorp-
tion of unconjugated bile acids increases in the middle
part of the small intestine, while active absorption of bile
acids in the distal part of the small intestine is probably
decreased. Taken together, our data showed that Ppars,
Lxrs and Fxr are substantially activated by the primary and
secondary metabolites of a high-fat diet and might there-
fore play an important role in regulation of small intesti-
nal lipid metabolism-related processes during high-fat
diet intervention.
Secretome analysis of differentially expressed genes in the 
small intestine after feeding a high-fat diet
Next to molecular changes that provoke local metabolic
effects in the small intestine, we also studied the differen-
tial gene expression of (novel) small intestinal secreted
proteins that are able to induce systemic effects. To iden-
tify the secreted proteins that are differentially expressed
during high-fat diet intervention, we performed a secre-
tome analysis. For this analysis, genes that were differen-
tially expressed in at least one week of diet intervention
(fold change >1.5) were additionally selected for their cor-
responding GO Cellular Component term 'extracellular
region/space' (GO:0005576/GO:0005615) (Figure 8).
Some of these selected genes showed a consistent differen-
tial gene expression throughout the small intestine and at
all time points (e.g. Angptl4, ApoC2, Dnase1, Cgref1, Gas6,
H2-Q10). Differential expression of others genes was
restricted to a more specific part of the gut (e.g. Cck, Gsn,
Dietary fat-induced cell proliferation in the small intestine,  analyzed by immunohistochemistry Figure 5
Dietary fat-induced cell proliferation in the small 
intestine, analyzed by immunohistochemistry. Immu-
nohistochemistry was performed on distal small intestinal 
sections of C57BL/6J mice fed a low-fat or high-fat diet using 
Ki67-specific antibodies. Besides the villus length (A) and 
total number of villus cells (B), also the number of Ki67-posi-
tive cells per villus (C) were determined. Per mouse, 15 villi 
were counted and the mean values were calculated. * p < 
0.05, # p = 0.07. LF = low-fat diet, HF = high-fat diet.
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Pap, Reg1, Fgf15, Ccl28, Pyy). For several genes, also a time
effect could be detected in their differential expression, as
they showed early (e.g. Igfbp4, Ttr) or late phase (e.g. Ccl5,
Ccl28,  Igj,  Fgf15) responses. Consistent with the ORA
analysis data described above, many of the secreted pro-
teins are related to lipid metabolism, especially chylomi-
cron synthesis (e.g. ApoA4, ApoC2, ApoC3), and
inflammation/immune response (e.g. several chemok-
ines, H2-Q10, Il18, Mif, Rsad2, Saa1/2). Although we do
not propose that all of these secreted proteins act as sign-
aling molecules that provoke a systemic effect on periph-
eral organs, we consider genes related to inflammation/
immune response and the gut hormones (e.g. Cck, Pyy) as
promising candidates. Also genes with a pronounced dif-
ferential gene expression, of which function is not com-
pletely elucidated yet (e.g. Angptl4, H2-Q10, Oit1,
Smpdl3a/b) are potential interesting signaling molecules
that might contribute to development of obesity and/or
insulin resistance.
Discussion
In this study, we demonstrated that C57BL/6J mice
develop obesity and glucose intolerance on a high-fat diet
that mimics the fatty acid composition of a Western-style
human diet. It might seem surprising that despite the iso-
energetic intake on the low- and high-fat diet, only mice
on a high-fat diet become obese. However, this can (at
least partly) be explained by the increased energy dissipa-
tion on the low-fat diet due to ATP requirement for the
conversion of glucose to fatty acids. This process occurs in
liver and adipose tissue of rodents [24], but is thought to
be of minor importance in humans on a Western-style
diet [25].
Microarray analyses of small intestinal mucosa showed
that dietary fat had the most pronounced effect in the
middle part of the small intestine. Furthermore, we found
that many dietary fat-induced molecular changes are
related to lipid metabolism, cell cycle and inflammation/
immune response. Although it seems obvious that lipid
metabolism with respect to fatty acid absorption and
transport is changed in the small intestine after feeding a
high-fat diet, it remains intriguing that also fatty acid oxi-
dation is elevated. So far, there is no solid explanation for
this, but we speculate that small intestinal fatty acid oxi-
dation is enhanced to prevent toxic accumulation of free
fatty acids in the enterocyte. In liver, muscle and adipose
tissue, chronic inflammation is also considered to be a key
player in the development of metabolic disorders [26]. In
the small intestine, however, we found no conclusive evi-
Relative mRNA expression of nuclear receptors along the longitudinal axis of the small intestine under basal conditions Figure 6
Relative mRNA expression of nuclear receptors along the longitudinal axis of the small intestine under basal 
conditions. For the proximal, middle and distal part of the small intestine, gene expression levels of Ppars, Lxrs and Fxr were 
determined after 2 weeks of low-fat diet intervention. qPCR data of the nuclear receptors are visualized as the mean expres-
sion of individual mice ± SE. Expression in the middle and distal part of the small intestine is relative to the expression in the 
proximal part, which was set to 1. a, b, and c indicate significant (p < 0.05, two-tailed Student's t test) differential gene expres-
sion between the distinct parts of the small intestine (a between the proximal and middle part, b between the middle and distal 
part and c between the proximal and distal part).
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dence for an increased inflammatory status that might
contribute to development of dietary fat-induced obesity
and insulin resistance.
Further analysis of our microarray data revealed that
nuclear receptors, such as Ppars, Lxr and Fxr play an
important role in the regulation of small intestinal metab-
olism after feeding a high-fat diet. Besides this, we also
found differential gene expression of signaling molecules
that can be secreted from the small intestinal mucosa and
provoke systemic effects. To determine the association of
these dietary-fat induced changes in the small intestine
with development of obesity and/or insulin resistance, we
linked them to previous data that were mainly obtained
by using null- and transgenic mice models (Table 1). We
consider the molecular changes that point into the right
direction (Table 1; shown in bold) to be potential small
intestinal effectors in the etiology of the metabolic syn-
drome. This will now be further discussed. Recently,
Tobin et al. reviewed the role of Ppars, Lxrs and Fxr in dis-
eases that are related to the metabolic syndrome [27].
However, these transcription factors were mainly studied
Dietary fat-induced differential expression of nuclear (hormone) receptors and their target genes in the small intestine Figure 7
Dietary fat-induced differential expression of nuclear (hormone) receptors and their target genes in the small 
intestine. For the proximal, middle and distal part of the small intestine, differential gene expression (indicated by fold 
changes) of nuclear (hormone) receptors and their target genes was determined by microarray analysis, after 2, 4, and 8 weeks 
of high-fat diet intervention. Red and green boxes indicate a significant up- and down-regulation, respectively. NC = no change, 
A = absent.
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Secretome analysis of differentially expressed genes in the small intestine during high-fat diet intervention Figure 8
Secretome analysis of differentially expressed genes in the small intestine during high-fat diet intervention. 
Secretome analysis was performed for the proximal, middle and distal part of the small intestine and included differentially 
expressed genes with fold changes < -1.5 and > +1.5 in at least one week of diet intervention. Red and green boxes indicate a 
significant up- and down-regulation, respectively. NC = no change, A = absent.
     proximal middle
  distal
Probe set ID  Gene name  Symbol  wk 2  wk 4 wk 8 wk 2  wk 4  wk 8  wk 2  wk 4  wk 8 
1451625_a_at  RIKEN cDNA 1700013L23 gene   1700013L23Rik  2.23  2.17  2.62  2.31  2.07  NC A  A  A 
1453132_a_at  RIKEN cDNA 1810036H07 gene   1810036H07Rik -4.44 3.73  NC  A A A A A A 
1428947_at  RIKEN cDNA 2010001M09 gene   2010001M09Rik NC  1.37  1.53  NC  1.77  1.82  -1.27 1.61  1.36 
1425233_at  RIKEN cDNA 2210407C18 gene  2210407C18Rik NC NC NC  1.22  1.26  1.26  1.55  3.05  1.35 
1417130_s_at angiopoietin-like  4  Angptl4  2.36  1.88  2.50  1.99  2.19  2.14  1.56  1.65  1.69 
1417761_at apolipoprotein  A-IV  Apoa4  NC NC  1.30  NC NC NC  3.16  2.17  3.20 
1418069_at apolipoprotein  C-II  Apoc2  1.40  1.32  1.57  1.91  1.91  1.68  11.08 8.06  9.00 
1418278_at apolipoprotein  C-III  Apoc3  -1.19 -1.13 NC NC NC NC  1.65  NC  1.40 
1446007_at Bone  morphogenetic  protein  1  Bmp1  NC NC  1.52  NC NC NC NC NC NC 
1455851_at  bone morphogenetic protein 5  Bmp5  NC NC NC NC NC NC  -1.62 NC NC 
1419473_a_at cholecystokinin  Cck  NC NC NC  1.59  1.35  1.42  1.45  NC NC 
1419426_s_at  chemokine (C-C motif) ligand 21  Ccl21  1.28  NC NC  2.46  NC  2.39  -1.57 NC NC 
1455577_at  Chemokine (C-C motif) ligand 28   Ccl28  NC NC NC NC NC NC NC  1.56  1.26 
1418126_at  chemokine (C-C motif) ligand 5   Ccl5  1.27  NC NC NC NC NC NC  1.84  1.89 
1417074_at  CEA-related cell adhesion molecule 10  Ceacam10  A  A  A  NC NC NC NC  6.45  5.10 
1424528_at  cell growth regulator with EF hand domain 1  Cgref1  1.36  1.25  1.31  1.72  1.49  1.36  1.68  NC  1.46 
1422632_at cathepsin  W  Ctsw  NC NC NC NC NC NC NC  1.67  NC 
1418652_at  chemokine (C-X-C motif) ligand 9  Cxcl9  NC NC NC NC NC NC NC  2.16  NC 
1424592_a_at deoxyribonuclease  I    Dnase1  1.28  1.60  1.84  1.54  1.47  1.46  1.89  1.40  1.54 
1418376_at  fibroblast growth factor 15  Fgf15  A A A A A A  NC  -1.27 -1.73
1417399_at  growth arrest specific 6  Gas6  -1.37 -1.39 -1.36 -1.85  -1.60  NC  -1.40 -1.31 NC 
1423404_at gastrokine  1  Gkn1  -4.29 3.48  NC  A A A A A A 
1415812_at gelsolin  Gsn  NC NC NC  -1.48  -1.59  -1.38 NC NC NC 
1416905_at  guanylate cyclase activator 2a (guanylin)  Guca2a  NC NC NC  -1.27  -1.55  -1.53 NC NC NC 
1417898_a_at granzyme  A  Gzma  NC NC NC NC NC NC NC  1.96  1.55 
1419060_at granzyme  B  Gzmb  NC NC NC NC  -1.25  -1.35 NC  2.57  NC 
1425137_at  histocompatibility 2, Q region locus 10  H2-Q10  8.11  9.00  8.46  13.55  11.71  7.84  8.40  2.53  2.50 
1423062_at  insulin-like growth factor binding protein 3  Igfbp3  1.59  NC  1.79  1.65  1.32  1.96  NC NC NC 
1437405_a_at  insulin-like growth factor binding protein 4  Igfbp4  NC NC NC NC NC NC  -1.51 -1.37 NC 
1423584_at  insulin-like growth factor binding protein 7  Igfbp7  NC NC NC  1.40  NC  1.62  NC NC NC 
1424305_at immunoglobulin  joining  chain  Igj  NC NC  1.42  NC  1.37  1.55  NC  1.59  1.41 
1417932_at interleukin  18  Il18  -1.30 -1.23 -1.44 -1.51  -1.28  -1.72 1.27  NC  -1.32
1449492_a_at  leukocyte cell-derived chemotaxin 2  Lect2  NC NC  1.68  2.10  1.32  NC A  A  A 
1438312_s_at  latent Tgf beta binding protein 3  Ltbp3  NC NC  -2.36 NC NC NC NC NC NC 
1416335_at  macrophage migration inhibitory factor  Mif  NC  1.16  NC  1.37  1.46  1.26  1.23  1.61  NC 
1424502_at  oncoprotein induced transcript 1  Oit1  1.44  1.41  1.39  2.62  3.29  2.10  NC  1.73  1.14 
1448290_at Pacreatitis-associated  protein  Pap  -2.45 -1.44 -1.93 -1.16  NC  NC  NC NC  NC 
1437453_s_at  proprotein convertase subtilisin/kexin type 9  Pcsk9  A A A  NC  NC  -3.25 NC NC  -1.32
1417426_at  proteoglycan 1, secretory granule  Prg1  NC NC NC NC NC  1.26  NC  1.71  1.29 
1431057_a_at protease,  serine,  23  Prss23  NC NC NC  -1.60  -1.85  -1.89 NC NC NC 
1424865_at peptide  YY  Pyy  A A A  1.67  NC  1.56  1.29  1.41  1.16 
1415905_at  regenerating islet-derived 1  Reg1  NC NC NC  -2.23  -2.83  -2.31 NC NC NC 
1424009_at  regenerating islet-derived 3 delta  Reg3d  -2.03 NC  -1.96 NC NC NC NC NC NC 
1448872_at  regenerating islet-derived 3 gamma  Reg3g  -2.31 -1.42 -2.48 -1.54  NC  -2.10 NC  1.21  NC 
1418931_at  regenerating islet-derived family, member 4  Reg4  NC NC  1.20  NC NC NC  -1.21 -1.65 -1.44
1436058_at  radical S-adenosyl methionine domain 2  Rsad2  NC  -1.45 -1.38 -2.14  -1.79  -1.55 NC NC NC 
1450788_at  serum amyloid A 1  Saa1  A A A A A A  -3.34 2.60  NC 
1449326_x_at  serum amyloid A 2  Saa2  A A A A A A  -2.51 1.89  NC 
1416635_at  sphingomyelin phosphodiesterase, acid-like 3A Smpdl3a  -1.35 -1.40 -1.37 -1.75  -1.82  -1.67 -1.29 NC NC 
1417300_at  sphingomyelin phosphodiesterase, acid-like 3B Smpdl3b  NC NC NC  -1.48  -1.40  -1.56 -1.45 NC NC 
1415871_at  transforming growth factor, beta induced  Tgfbi  -1.46 -1.45 -1.39 NC NC NC  -1.57 -1.17 NC 
1455913_x_at transthyretin  Ttr  NC NC NC  1.45  1.57  NC NC NC NC 
1426399_at  von Willebrand factor A domain containing 1  Vwa1  NC  -1.24 NC  -1.39  -1.28  NC NC  -1.40 1.57 BMC Medical Genomics 2008, 1:14 http://www.biomedcentral.com/1755-8794/1/14
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in liver, muscle and white adipose tissue and little is
known so far about their small intestinal function. In our
study, we found an elevated expression of many target
genes of Ppars, especially of Pparα, which are involved in
lipid metabolism-related processes, such as fatty acid
transport and fatty acid oxidation. Previous studies
showed that Pparα null mice become more obese on a
high-fat diet than wild-type mice, but are resistant to die-
tary fat-induced insulin resistance [28,29]. With regard to
our study this might suggest that an elevated activation of
Pparα in the small intestine can contribute to develop-
ment of insulin resistance on a high-fat diet. As in null
mice, the lack of Pparα is associated with obesity it is hard
to directly link our Pparα-related gene expression data to
this metabolic disorder. However, Kondo et al. recently
showed that a suboptimal activation of Pparα and there-
fore an impaired fatty acid oxidation in the small intestine
of C57BL/6J mice might also contribute to the develop-
ment of dietary fat-induced obesity [5]. Interestingly, the
decreased expression of Pgc1α that we found in our study
might point in the direction of a suboptimal activation of
Pparα, as it is known that Pgc1α can cooperatively induce
the expression of Pparα target genes and increase cellular
fatty acid oxidation rates [30]. Moreover, a decreased
expression of Pgc1α was previously already linked to an
inefficient fatty acid oxidation [31]. The continuous
down-regulation of Pparδ in the middle part of the small
intestine might also be related to development of insulin
resistance, as Pparδ null mice become more glucose intol-
erant on a high-fat diet [32]. Taken together, Ppars and
their co-activator Pgc1α might be substantial small intes-
tinal contributors to development of obesity and/or insu-
lin resistance. For Lxr target genes Abca1, Scd1 and Srebf1
(encodes for sterol regulatory element binding protein 1c
(Srebp1c)), a similar discrepancy as was seen for their
small intestinal gene expression on a high-fat diet was
reflected in the susceptibility of the corresponding null
mice to develop obesity and/or insulin resistance (Table
1). Abca1 null mice become more glucose intolerant,
whereas Scd1 and Srebp1c null mice are protected against
these diet-induced metabolic disorders [33-35]. There-
fore, dietary fat-induced down-regulation of Abca1 and
up-regulation of Scd1  and  Srebf1  might contribute to
development of obesity and/or insulin resistance. The
strong up-regulation of Fxr target gene Shp in the middle
part of the small intestine might also be involved in devel-
opment of these metabolic diseases, as previous null mice
studies showed that mice lacking Shp are resistant to die-
tary fat-induced obesity and insulin resistance [36]. More-
over, the study of Wang et al. [36] implied that high
expression levels of Shp might be correlated with
decreased levels of Pgc1α. Our study also shows an inverse
relationship between the expression of Shp and Pgc1α.
Exploration of the small intestinal function of Abca1,
Scd1, Srebp1c and Shp might further elucidate their
potential role in development of obesity and/or insulin
resistance.
Various signaling molecules that we found differentially
expressed in the small intestine after exposure to a high-
fat diet were previously associated with excessive weight
gain and an impaired glucose homeostasis. A recent study
showed that mice lacking the inflammatory cytokine
interleukin 18 (Il18) have markedly increased body
weight and are insulin resistant [37,38]. It is even sug-
gested that Il18 possesses a glucose-lowering potential.
The continuous decreased expression of Il18 in the proxi-
mal and middle part of the small intestine that we found
after a high-fat diet intervention might suggest a role in
dietary fat-induced obesity and insulin resistance. Next to
Il18, macrophage inhibitory factor (Mif) is a pro-inflam-
matory cytokine that we found up-regulated in the small
intestine by dietary fat. This increased expression might
contribute to elevated plasma levels of Mif that are previ-
ously related to obesity and insulin resistance [39,40].
Furthermore, Fgf15 expression is thought to be inversely
associated with development of insulin resistance [41],
whereas a positive correlation is reported for expression of
insulin-like growth factor binding protein 3 (Igfbp3) [42].
In accordance with these previous studies, we found a
down-regulation of Fgf15 in the distal small intestine and
an up-regulation of Igfbp3 in the proximal parts of small
intestine after feeding a high-fat diet. Previous studies
showed that suppression of Angptl4 by gut microbiota,
was related to dietary fat-induced obesity [6]. In contrast,
we found a continuous up-regulation of this gene in all
parts of the small intestine. This implies that in our
C57BL/6J mice, the gut microbiota was not able to sup-
press Angptl4 on a high-fat diet. Nevertheless, the mice
still became obese. Therefore, we conclude that small
intestinal Angptl4 is probably not a main contributor to
development of obesity in our mouse model. Interest-
ingly, however, studies of Mandard et al. showed that ele-
vated levels of Angptl4 in blood are related to glucose
intolerance [43]. This might indicate that the dietary-fat
induced up-regulation of Angptl4 in the small intestine
can provoke a systemic effect on development of insulin
resistance. Moreover, a recent study of Desai et al. indi-
cates that Angptl4 plays an important role in the small
intestine [44]. They showed that Angptl4 null mice dis-
play severe intestinal pathology, especially abnormalities
of intestinal lymphatics, which even deteriorated after
feeding a high-fat diet. Further research will be required to
more accurately elucidate the function of Angptl4, but
also of Il18, Fgf15, Mif and Igfbp3 in the small intestine
and their possible role in the etiology of the metabolic
syndrome. For the incretin hormones, gastric inhibitory
polypeptide and glucagon-like peptide-1, that are fre-
quently associated with insulin sensitivity we found
hardly any changes in gene expression on a high-fat diet.BMC Medical Genomics 2008, 1:14 http://www.biomedcentral.com/1755-8794/1/14
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Therefore, in our study the incretins probably do not con-
tribute to the development of dietary fat-induced insulin
resistance in the C57BL/6J mice.
Conclusion
During development of obesity and insulin resistance,
biological processes related to lipid metabolism, cell cycle
and inflammation/immune response are most strongly
modulated in the small intestine of C57BL/6J mice fed a
high-fat diet that mimics the fatty acid composition of a
Western-style human diet. Our data further indicate that
Ppars, Lxrs and Fxr are important metabolic regulators in
the response of the small intestine to dietary fat. Next to
these local small intestinal effects of a high-fat diet, we
also found modulated expression of secreted proteins,
such as Il18, Fgf15, Mif, Igfbp3 and Angptl4. These signal-
ing molecules might provoke metabolic effects in liver,
muscle and adipose tissue that underlie the development
of the metabolic syndrome. Finally, as many of the die-
tary-fat induced molecular changes in the small intestine
point in the same direction as data from previous null-
and transgenic mouse studies, we propose these changes
to be plausible effectors illustrating the role of the small
intestine in the etiology of the metabolic syndrome.
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Table 1: Obesity- and/or insulin resistance-associated genes and their expression in the small intestine of C57BL/6J mice fed a high-fat 
diet.
Gene name (symbol) Previous association with obesity and/or 
insulin resistance (ref.)
Transcriptional regulation in small 
intestine on a HF diet
Nuclear receptors & target genes
ATP-binding cassette, sub-family A, 1 
(Abca1)
-/- mice; IR   [45] ↓ P, M, D
Farnesoid X-activated receptor (Fxr, 
Nr1h4)
-/- mice; IR   [46, 47] minimal regulation, but target genes:
↑ P, M; ↓ D
Liver X receptor (LXRα/β, Nr1h2/3) -/- mice; obesity & IR   [48] minimal regulation, but target genes:
cholesterol metabolism ↓ P, M, D
fatty acid metabolism ↑ P, M
Peroxisome proliferator activated 
receptor α (Pparα)
-/- mice; obesity  , IR   [28, 29] minimal regulation, but target genes:
↑ P, M, D
Peroxisome proliferator activated 
receptor δ (Pparδ)
-/- mice; IR   [32] ↓, M
Peroxisome proliferator activated 
receptor γ (Pparγ)
-/+ mice; IR  
Agonists (TZDs) used as anti-diabetic agents
[49, 50] minimal regulation
Pparγ, coactivator 1α (Pgc1α) -/- mice; obesity  , IR   [51] ↓ M
Stearoyl-Coenzyme A desaturase 1 (Scd1) -/- mice; obesity & IR   [33, 34] ↑ P, M, D
Sterol regulatory element binding factor 1 
(Srebf1)
-/- mice; obesity   [35] ↑ P
Small heterodimer partner (Shp, Nr0b2) -/- mice; obesity & IR   [36] ↑ P, M
Secreted (signaling) proteins
Angiopoietin-like 4 (Angptl4) Tg mice; obesity  , IR  
Suppression by gut microbiota promotes 
triglyceride storage
[6] ↑ P, M, D
Fibroblast growth factor 15 (Fgf15) Injection of Fgf15; glucose tolerance   [41] ↓ D
Glucagon-like peptide-1 (Glp1) High plasma levels; IR   [12, 13] ↑ (slightly) M
Gastric inhibitory polypeptide (Gip) High plasma levels; IR   [13] ↑ (slightly) D
Insulin-like growth factor binding protein 
3 (Igfbp3)
Tg mice; IR   [42] ↑ P, M
Interleukin 18 (Il18) -/- mice; obesity & IR   [37] ↓ P, M
Macrophage migration inhibitory factor 
(Mif)
High plasma levels; obesity & IR   [39] ↑ M, D
-/- mice: null mice, +/- mice: heterozygous mice, Tg mice: transgenic mice, IR: insulin resistance, P, M, D: proximal, middle, distal part of the small 
intestine,  : prone to,  : resistant to, ↑: up-regulated expression, ↓: down-regulated expression. In bold: dietary-fat induced molecular changes in the 
small intestine that point in the same direction as data from previous null- and transgenic mouse studies regarding development of metabolic 
syndrome.BMC Medical Genomics 2008, 1:14 http://www.biomedcentral.com/1755-8794/1/14
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